Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Emily Hayes
Emerging Company Profile: The start-up's Phase I and II studies look promising for stem cell therapy in treating aging frailty, a common condition that overlaps with Alzheimer's disease.
The commercial team is on board and ready to market the first FDA-approved RNAi therapeutic patisiran for hereditary transthyretin-mediated amyloidosis.
Company reported only $33,000 in sales for late anticoagulant market entrant Bevyxxa and $2.2m for the antidote Andexxa, leaving a lot of challenges ahead after the retirement of CEO Bill Lis, effective Aug. 1.
Recorlev (levoketoconazole) demonstrates efficacy and liver safety in a Phase III single-arm study, but needs to live down the bad rap of ketoconazole and ultimately escape a black box warning.
Company explains how it will design upcoming Phase III hemophilia A study of SPK-8011 for success, but some analysts still think it's risky business.